Literature DB >> 25929666

Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.

A Siri1, Clarisse Carra-Dalliere, X Ayrignac, J Pelletier, B Audoin, S Pittion-Vouyovitch, M Debouverie, C Lionnet, F Viala, D Sablot, D Brassat, J-C Ouallet, A Ruet, B Brochet, L Taillandier, L Bauchet, N Derache, G Defer, P Cabre, J de Seze, C Lebrun Frenay, M Cohen, P Labauge.   

Abstract

Isolated tumefactive demyelinating lesion (TDL) is a rare disease and a challenging entity especially for the differential diagnosis, biopsy indications, and therapeutic decisions. Long-term evolution is not well known. The objective of the study is to describe clinical and MRI characteristics and long-term follow-up of patients with isolated TDL. We performed a retrospective study including patients (1) with one TDL radiologically defined by a ≥20 mm FLAIR hyperintensity involving the white matter associated with T1 hypointensity that enhanced after gadolinium injection and (2) without any other MS lesion on the first MRI. Tumor, abscess, or other inflammatory diseases (ADEM, Baló's concentric sclerosis, systemic disease) were excluded. Sixteen patients (11 females/5 males) were included. The mean age of onset was 35.7 years (range 20-65). MRI disclosed supratentorial lesions with a mean size of 39.4 mm and usually mild edema/mass effect. Peripheral (mainly open-ring pattern) and central (mainly heterogeneous) enhancement were respectively seen in 9/16 and 11/16 patients. CSF study (n = 15) found oligoclonal bands (OCB) in seven. A cerebral biopsy was performed in 11 cases showing acute inflammatory demyelination. Thirteen patients were treated by pulse steroids with marked improvement in ten. At last clinical follow-up (mean 65.8 months, range 6-181), diagnosis was MS in 5 (31 %), isolated TDL in 10 (63 %) and one patient had a second TDL (6 %). Isolated tumefactive demyelinating lesions are a rare diagnostic entity. After a mean follow-up of 5 years, almost one-third became MS whereas most of the patients had no further event.

Entities:  

Mesh:

Year:  2015        PMID: 25929666     DOI: 10.1007/s00415-015-7758-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  20 in total

1.  Relapsing-remitting tumefactive multiple sclerosis.

Authors:  Stephen M Selkirk; Jiong Shi
Journal:  Mult Scler       Date:  2005-12       Impact factor: 6.312

2.  Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm.

Authors:  Takao Kiriyama; Hiroshi Kataoka; Toshiaki Taoka; Yasuyo Tonomura; Mari Terashima; Masami Morikawa; Emi Tanizawa; Makoto Kawahara; Yoshiko Furiya; Kazuma Sugie; Kimihiko Kichikawa; Satoshi Ueno
Journal:  J Neuroimaging       Date:  2011-04       Impact factor: 2.486

3.  Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy.

Authors:  G M Nesbit; G S Forbes; B W Scheithauer; H Okazaki; M Rodriguez
Journal:  Radiology       Date:  1991-08       Impact factor: 11.105

4.  Open-ring imaging sign: highly specific for atypical brain demyelination.

Authors:  J C Masdeu; C Quinto; C Olivera; M Tenner; D Leslie; P Visintainer
Journal:  Neurology       Date:  2000-04-11       Impact factor: 9.910

5.  Clinical and radiological characteristics of 17 Chinese patients with pathology confirmed tumefactive demyelinating diseases: follow-up study.

Authors:  Jiarui Yao; Dehui Huang; Qiuping Gui; Xiaolei Chen; Xin Lou; Lei Wu; Chen Cheng; Jie Li; Weiping Wu
Journal:  J Neurol Sci       Date:  2014-12-03       Impact factor: 3.181

6.  Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients.

Authors:  J J Kepes
Journal:  Ann Neurol       Date:  1993-01       Impact factor: 10.422

7.  Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: review of the literature and treatment proposal.

Authors:  Jahannaz Dastgir; Francis J DiMario
Journal:  J Child Neurol       Date:  2009-02-02       Impact factor: 1.987

Review 8.  Tumefactive demyelination: an approach to diagnosis and management.

Authors:  Todd A Hardy; Jeremy Chataway
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-01-19       Impact factor: 10.154

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

10.  Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis.

Authors:  C F Lucchinetti; R H Gavrilova; I Metz; J E Parisi; B W Scheithauer; S Weigand; K Thomsen; J Mandrekar; A Altintas; B J Erickson; F König; C Giannini; H Lassmann; L Linbo; S J Pittock; W Brück
Journal:  Brain       Date:  2008-06-05       Impact factor: 13.501

View more
  7 in total

Review 1.  Brain metastases: neuroimaging.

Authors:  Whitney B Pope
Journal:  Handb Clin Neurol       Date:  2018

2.  Acute multiple sclerosis lesion pathology does not predict subsequent clinical course-a biopsy study.

Authors:  Hugh Kearney; Tucker Price; Jane Cryan; Alan Beausang; Seamus Looby; Francesca M Brett; Michael Farrell
Journal:  Ir J Med Sci       Date:  2019-02-15       Impact factor: 1.568

3.  Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.

Authors:  G Balloy; J Pelletier; L Suchet; C Lebrun; M Cohen; P Vermersch; H Zephir; E Duhin; O Gout; R Deschamps; E Le Page; G Edan; P Labauge; C Carra-Dallieres; L Rumbach; E Berger; P Lejeune; P Devos; J-B N'Kendjuo; M Coustans; E Auffray-Calvier; B Daumas-Duport; L Michel; F Lefrere; D A Laplaud; C Brosset; P Derkinderen; J de Seze; S Wiertlewski
Journal:  J Neurol       Date:  2018-07-27       Impact factor: 4.849

4.  Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.

Authors:  Matthew A Tremblay; Javier E Villanueva-Meyer; Soonmee Cha; Tarik Tihan; Jeffrey M Gelfand
Journal:  J Neurol Sci       Date:  2017-08-10       Impact factor: 3.181

5.  Commentary: Tumefactive Demyelinating Lesions as a First Clinical Event: Clinical, Imaging, and Follow-up Observations.

Authors:  Tatiana Koudriavtseva; Domenico Plantone
Journal:  Front Neurol       Date:  2016-12-05       Impact factor: 4.003

Review 6.  A challenging diagnosis of late-onset tumefactive multiple sclerosis associated to cervicodorsal syringomyelia: doubtful CT, MRI, and bioptic findings: Case report and literature review.

Authors:  Renata Conforti; Raffaella Capasso; Rosario Galasso; Mario Cirillo; Gemma Taglialatela; Luigi Galasso
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

7.  Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases.

Authors:  Aigli G Vakrakou; Dimitrios Tzanetakos; Maria-Eleptheria Evangelopoulos; Theodore Argyrakos; John S Tzartos; Maria Anagnostouli; Elissavet Andreadou; Georgios Koutsis; Georgios Velonakis; Panagiotis Toulas; Elias Gialafos; Antonios Dimitrakopoulos; Erasmia Psimenou; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Ther Adv Neurol Disord       Date:  2021-05-18       Impact factor: 6.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.